DHSC

Lib Dem proposals take social care reform seriously – but doubts remain over how they’d pay for it

Retrieved on: 
Mittwoch, Juni 12, 2024
International, Liberal Democrats, ESRC, NHS, NIHR, Bucking, Health, CC, Thought, Liberal Democrats (UK), Policy, Democrat, Workforce, Innovation, Woman, Digital, Health Foundation, Empowerment, Innovate UK, Risk, Research, Child, DHSC, Pressure, Liberal

Despite the fact that it is central to so many people’s lives, too often, social care is an afterthought for UK political parties.

Key Points: 
  • Despite the fact that it is central to so many people’s lives, too often, social care is an afterthought for UK political parties.
  • In the first TV debate of the 2024 general election, Rishi Sunak and Keir Starmer devoted only 36 seconds to this issue.
  • Leader Ed Davey has made a strong personal commitment to care, detailing on camera what his role as a carer for his disabled son entails.
  • The party has made social care reform one of its key policy commitments.

Free personal care

  • The most eye-catching commitment in the Lib Dem manifesto is to introduce free personal care.
  • Making personal care free focuses attention on a narrow and functional set of tasks, rather than focusing on what people actually need to live a good life.
  • Mostly, it can mislead people into thinking that care is free, whereas there are still major costs such as the accommodation charges in care homes.

Workforce retention

  • They also want to ensure experienced staff feel more valued, in order to improve retention.
  • Focusing on workforce issues is critical.

Unpaid carers

  • The Lib Dems also promise to improve the calamitous situation currently facing unpaid carers.
  • The party aims to reform the Carers Allowance, which is much needed.
  • Fundamentally, the Carers Allowance is an archaic benefit in need of a comprehensive reappraisal.

Digital care infrastructure

IC-266747-C7Q6

Retrieved on: 
Sonntag, Juni 2, 2024
Commissioner, FOIA, DHSC

The complainant has requested a list of responders to a consultation on planned advertising restriction for foods high in fat, salt and sugar along with the submissions from these responders. The DHSC provided the list of responders and the request was refined to the first five pages of submissions which the DHSC provided in redacted form with information exempt under section 35(1)(a) and 43(2) FOIA. The Commissioner’s decision is that the DHSC has failed to demonstrate that the section 43(2) exemption is engaged. Section 35(1)(a) is engaged but the public interest favours disclosure. The Commissioner requires DHSC to provide the complainant with a copy of the information it withheld from the submissions under section 35(1)(a) and 43(2).

Key Points: 
  • The DHSC provided the list of responders and the request was refined to the first five pages of submissions which the DHSC provided in redacted form with information exempt under section 35(1)(a) and 43(2) FOIA.
  • The Commissioner’s decision is that the DHSC has failed to demonstrate that the section 43(2) exemption is engaged.
  • Section 35(1)(a) is engaged but the public interest favours disclosure.
  • The Commissioner requires DHSC to provide the complainant with a copy of the information it withheld from the submissions under section 35(1)(a) and 43(2).

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Retrieved on: 
Dienstag, Januar 16, 2024
Development, Agreement, Patient, Infection, Ceftriaxone, Infertility, Social work, Science, Gonorrhea, STI, Administration, Pelvic inflammatory disease, Vaccination, Bill, Risk, Education, Bacteria, Neisseria gonorrhoeae, Disease, BMBF, Doctor of Philosophy, HIV, Human services, Vaccine, Chronic pain, DHSC, OMV

The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.

Key Points: 
  • The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.
  • Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.
  • Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
  • “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections.

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

Retrieved on: 
Dienstag, Dezember 19, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Rabbit, Infection, Multimedia, NIAID, Toxoid, Administration, Staphylococcus aureus, Mouse, Doctor of Philosophy, Recurrence, DHSC, Human services, REPAIR, Education, Bangladesh Technical Education Board, S. aureus, Staphylococcus, Patient, Development, BMBF, Social work, Skin, CARB-X, Vaccine

LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).

Key Points: 
  • LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).
  • LimmaTech also receives an exclusive option, executable post Phase 1 read-out, to acquire full rights to the program.
  • The vaccine candidate contains weakened forms of toxins, referred to as toxoids, that would normally be secreted by the pathogen to cause an infection.
  • Preclinical studies in mice and rabbits demonstrated strong neutralizing activity against several clinically relevant forms of S. aureus infection.

Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus

Retrieved on: 
Freitag, November 17, 2023
UK Research and Innovation, Orthornavirae, Low, Good manufacturing practice, CHIKV, MHRA, Disease, DHSC, Government, Epitope, Epidemic, Research, Swiss Medical Students' Association, UKRI, Arthritis, Vaccine, AMR, CD8, Infection, CGMP, Pacific Ocean, News, RNA, Social work, Chikungunya, Dengue fever

In the last decade, CHIKV has become a reemerging mosquito-transmitted virus that has spread into Europe, Asia, the Pacific Region, and the Americas, with epidemics causing severe economic impact.

Key Points: 
  • In the last decade, CHIKV has become a reemerging mosquito-transmitted virus that has spread into Europe, Asia, the Pacific Region, and the Americas, with epidemics causing severe economic impact.
  • The programme is intended to position Emergex for entry to the clinic by its completion, ready to begin a Phase-1 clinical trial.
  • Subsequently, Emergex achieved all milestones priming the CHIKV candidate for progression to the next stage of its preclinical development.
  • A Phase-2 trial for CoronaTcP and a Phase-1 trial for a Universal Influenza vaccine candidate are planned in H1 2024.

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Mittwoch, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Protecting privacy during a pandemic: our work on the UK’s Covid apps

Retrieved on: 
Dienstag, April 25, 2023
Technology, Department, Social work, Health Protection Scotland, NHS COVID-19, ICO, API, DHSC, Privacy, Government, Department of Health and Social Care, NI, Health, Mobile phone

He led our operational response to the pandemic and leads our stakeholder relationships with the health and care sector.

Key Points: 
  • He led our operational response to the pandemic and leads our stakeholder relationships with the health and care sector.
  • In practice, the majority of our work to protect people’s privacy rights has a far lower profile.
  • Our work with the Department of Health and Social Care and Welsh Government around the NHS Covid app is a prime example.
  • We’re pleased that our work, started in March 2020, has helped to protect millions of people across the UK.

Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine

Retrieved on: 
Montag, November 28, 2022
Degenerative disease, MHC, Infection, UK Research and Innovation, Epitope, Public health, Innovation, Peptide, Laboratory, Allele, HLA, RNA, Cell, Developing country, IUK, Alphavirus, Department of Health and Social Care, Global health, Research, Medicine, Disease, UKRI, Government of the United Kingdom, Social work, CD8, Immortalised cell line, Human, DHSC, Organic acid, HLA-C, Vaccine, Pharmaceutical industry, Chikungunya, CHIKV

Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.

Key Points: 
  • Abingdon, Oxon, UK, 28 November 2022 Emergex Vaccines Holding Limited (Emergex), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces today that it has generated a Chikungunya (CHIKV) ligandome, the first major milestone in the development of Emergexs CD8+ T cell CHIKV Adaptive Vaccine candidate.
  • The library of CHIKV ligandome peptides identified by Emergex will now enter the next phase of development.
  • Laurens Rademacher, Chief Technology Officer at Emergex commented: The ligandome identified allows the addition of a Chikungunya vaccine candidate to Emergexs pipeline.
  • The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.

DXC Technology Rolls Out Global Initiative to Support Neurodiversity in the Workplace

Retrieved on: 
Mittwoch, Oktober 12, 2022
Dyslexia, Technology, DHSC, EMEA, Cornell University School of Industrial and Labor Relations, Employment, Motivation, Disability studies, Department of Health and Social Care, NYSE, ADHD, UX, APAC, DXC Technology, Program, Autism, Workforce, Partnership, Cornell University, Department, Information technology, Social work, Information management, Workplace, United Kingdom, Environment, Foundation, DXC, Disability, Consultant, Management, Risk management, Creative industries

LONDON, Oct. 12, 2022 /PRNewswire/ -- DXC Technology (NYSE: DXC) a leading Fortune 500 global technology services provider, is expanding the DXC Dandelion Program which helps neurodivergent individuals with autism, ADHD, dyslexia and other neurological conditions to build careers in the IT industry.

Key Points: 
  • Following the success of the program in Australia and New Zealand, DXC is now launching the initiative across European and Asia Pacific countries.
  • The DXC Dandelion Program was launched in 2014 in Australia with a focus on creating employment pathways and careers for neurodivergent individuals within the IT industry.
  • With no prior professional experience required to participate, DXC has made the program available to individuals of all abilities with the motivation to work in technology.
  • In addition to offering employment, DXC provides participants with technical and vocational training plus professional support by specialised consultants.

DXC Technology Rolls Out Global Initiative to Support Neurodiversity in the Workplace

Retrieved on: 
Mittwoch, Oktober 12, 2022
Dyslexia, Technology, DHSC, EMEA, Cornell University School of Industrial and Labor Relations, Employment, Motivation, Disability studies, Department of Health and Social Care, NYSE, ADHD, UX, APAC, DXC Technology, Program, Consultant, Autism, Workforce, Multimedia, Partnership, Cornell University, Department, Information technology, Social work, Information management, Workplace, United Kingdom, Environment, Foundation, DXC, Disability, View, Management, Risk management, Creative industries

Following the success of the program in Australia and New Zealand, DXC is now launching the initiative across European and Asia Pacific countries.

Key Points: 
  • Following the success of the program in Australia and New Zealand, DXC is now launching the initiative across European and Asia Pacific countries.
  • The DXC Dandelion Program was launched in 2014 in Australia with a focus on creating employment pathways and careers for neurodivergent individuals within the IT industry.
  • With no prior professional experience required to participate, DXC has made the program available to individuals of all abilities with the motivation to work in technology.
  • In addition to offering employment, DXC provides participants with technical and vocational training plus professional support by specialised consultants.